FierceBiotech 16 abr 2026 Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
FierceBiotech 6 abr 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech 1 abr 2026 Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
FierceBiotech 1 abr 2026 Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
FierceBiotech 23 mar 2026 Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
FierceBiotech 12 mar 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
FierceBiotech 4 mar 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 25 feb 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
FierceBiotech 6 feb 2026 Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
FierceBiotech 4 feb 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 3 feb 2026 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
FierceBiotech 3 feb 2026 Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
FierceBiotech 21 ene 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech 20 ene 2026 Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
FierceBiotech 9 ene 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential